nanotechnology, nanotechnology links, nanomaterials, nanomaterial database, nanotechnology news
Nanowerk article print Printer-friendly
Nanowerk article email E-mail this article
Nanowerk news digest Daily News Email Digest
Subscribe to Nanowerk Spotlight Subscribe to Spotlight
Nanowerk on Facebook Join us on Facebook
Nanowerk on Twitter Follow us on Twitter
Nanowerk News Feeds Nanowerk News Feeds
Bookmark Nanowerk Story
Nanotechnology Top 10 Articles
Posted: Nov 19th, 2009
Posted: Nov 18th, 2009
Posted: Nov 17th, 2009
Posted: Nov 16th, 2009
Posted: Nov 12th, 2009
Posted: Nov 10th, 2009
Posted: Nov 9th, 2009
Posted: Nov 5th, 2009
Posted: Nov 4th, 2009
Posted: Nov 3rd, 2009
Posted: Nov 2nd, 2009
Posted: Oct 30th, 2009
Posted: Oct 28th, 2009
Posted: Oct 27th, 2009
Posted: Oct 26th, 2009
Posted: Oct 23rd, 2009
Posted: Oct 22nd, 2009
Posted: Oct 21st, 2009
Posted: Oct 16th, 2009
...more nanotechnology articles
 
Posted: May 24, 2006
Using nanofibers to repair the heart
(Nanowerk Spotlight) The human heart does not have significant regeneration capabilities and cardiologists look to cell therapy as a promising new method for cardiac repair. Now there is a new delivery system that improves the results of cell therapy. The new system allows greater control of the intramyocardial environment (inside the heart muscle) by delivering growth factors to an injured heart muscle and using peptide nanofibers for prolonged delivery of the injected factor.
Dr. Richard T. Lee, a cardiologist at Harvard Medical School's Brigham and Women's Hospital (BWH), explained their recent research to Nanowerk: "One of the big problems with cell therapy is that once you inject cells into the body, you lose control over their environment. In the laboratory, we have tight control of conditions and can add growth factors, for example, whenever we want. The main finding of our study is that you can delivery growth factors to the environment around injected cells using nanofibers."
Dr. Lee's recent paper, titled "Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction" was published in the May 12, 2006 online edition of Proceedings of the National Academy of Sciences (PNAS). The paper was first authored by Michael E. Davis and co-authored by collaborators from BWH and the Division of Biological Engineering at MIT.
"Most past studies inject proteins directly into tissues like the heart" Lee says. "Many proteins delivered this way don't stay in the tissue very long. Our new technology allows the growth factor to be delivered for many weeks in a highly controlled way."
Repairing the heart by using cell therapy is a very promising new approach to cardiac repair. However, studies to date indicate that few transplanted cells engraft and ultimately function normally within the host tissue. The shortcoming of many therapeutic strategies is the lack of quantitative control of transplanted cells in their new environment.
Substantial data suggest that insulin-like growth factor 1 (IGF-1) is a potent cardiomyocyte growth and survival factor. IGF-1 overexpression increases cardiac stem cell number and growth, leading to an increase in myocyte turnover and function in the aging heart. However, IGF-1 is a small protein that diffuses readily through tissues, which restricts its retention within these tissues for prolonged periods.
Self-assembling peptides are oligopeptides (polypeptides less than 30-50 amino acids long) composed of alternating hydrophilic and hydrophobic amino acids. On exposure to physiological osmolarity and pH, the peptides rapidly assemble into small nanofibers (10 nm) that can be injected into the heart muscle to form 3D cellular microenvironments. These peptide nanofiber microenvironments recruit a variety of cells including vascular cells.
Lee explains: "In our article, we describe development of a delivery system using a "biotin sandwich" approach that allows coupling of a growth factor to peptide nanofibers without interfering with self-assembly. Biotinylation of self-assembling peptides allowed specific and highly controlled delivery of IGF-1 to local myocardial microenvironments, leading to improved results of cell therapy."
Streptavidin-binding to the biotinylated peptides. (A) Binding curve demonstrating the binding capacity of 35S-streptavidin to biotinylated selfassembling peptides. (B) AFM images of the biotinylated self-assembling peptide nanofibers alone (Left), streptavidin alone (Center), or streptavidin coupled to the biotinylated self-assembling peptide nanofibers (Right). Arrows show spherical streptavidin molecules. (Reprinted with permission from PNAS)
"Although we describe controlled myocardial delivery here, this approach may be used to delivery one factor or even multiple factors to tissues for prolonged periods" Lee says.
This ability to control the local myocardial microenvironment may prove critical to preventing heart failure.
Lee concludes: "We think this is just the beginning of how we can design the local environment around cells to encourage them to do things that can help the injured tissue. We just delivered one factor, but there's no reason you can't deliver many factors that are needed."
By Michael Berger, Copyright 2006 Nanowerk LLC. All rights reserved.
Bookmark Nanowerk Directory
Subscribe! Receive a convenient email notification whenever a new Nanowerk Nanotechnology Spotlight posts.
Become a Spotlight guest author! Have you just published a scientific paper or have other exciting developments to share with the nanotechnology community? Let us know.
 
 
 
Privacy statement | Terms of use | Contact us | Home | Sitemap | Advertise with us
The contents of this site are copyright ©2009, Nanowerk LLC. All Rights Reserved